Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: We evaluated whether a daily nasal spray of interferon-alpha (IFN-α) would reduce the incidence of COVID-19 or community-acquired respiratory viral infections in adult cancer patients.
Methods: In this multicenter, randomized, double-blinded, placebo-controlled trial, participants were randomized 1:1 to receive daily 40 000 IU IFN-α nasal spray or normal saline placebo. Participants who developed influenza-like symptoms self-collected nasal swabs for PCR testing of SARS-CoV-2, influenza A/B, respiratory syncytial virus, parainfluenza, adenovirus, seasonal coronavirus, picornavirus, human metapneumovirus, and/or SARS-CoV-2 rapid antigen testing. Co-primary endpoints were incidence of COVID-19 and/or other respiratory viruses ≤90 days of randomization.
Results: Four hundred and thirty-three participants were randomized to IFN-α (n = 217) or placebo (n = 216). The incidence of COVID-19 was lower in the IFN-α group versus placebo (8.3% vs 14.4%), indicating a 40% reduced risk of infection (relative risk [RR]: .60; 95% credible interval [CrI]: .33-.97). Other respiratory viral infection incidence was 5.1% and 5.1% in both groups (RR: 1.12; .43-2.34). In the per-protocol cohort (n = 389), the incidence of COVID-19 in IFN-α and placebo groups was 7.7% and 16.0% (RR: .50; .26-.84) with other respiratory virus incidence of 4.6% and 5.7%, respectively. Subgroup analysis demonstrated lower COVID-19 in the IFN-α group for ages <65 years (RR: .48; .20-.92), female sex (RR: .44; .19-.85), and COVID-19 vaccinated (RR: .50; .26-.82), but no difference by underlying malignancy. No differences were observed in secondary endpoints of severity, hospitalization, and mortality. IFN-α was well tolerated and safe.
Conclusions: IFN-α nasal spray prophylaxis reduced the incidence of COVID-19 among adult cancer patients.
Clinical Trials Registration: ClinicalTrials.gov identifier: NCT04534725 (ANZCTR: ACTRN12620000843954).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciaf409 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave.
BMC Glob Public Health
September 2025
Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Background: Between November 2023 and March 2024, coastal Kenya experienced another wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections detected through our continued genomic surveillance. Herein, we report the clinical and genomic epidemiology of SARS-CoV-2 infections from 179 individuals (a total of 185 positive samples) residing in the Kilifi Health and Demographic Surveillance System (KHDSS) area (~ 900 km).
Methods: We analyzed genetic, clinical, and epidemiological data from SARS-CoV-2 positive cases across pediatric inpatient, health facility outpatient, and homestead community surveillance platforms.
Experiencing stigmatization during the COVID-19 pandemic: a qualitative study among healthcare workers.
BMC Infect Dis
September 2025
Department Health and Prevention, Institute of Psychology, University of Greifswald, Robert-Blum-Str. 13, Greifswald, 17489, Germany.
Background: Healthcare workers (HCWs) played a crucial role in dealing with the COVID-19 pandemic. In addition to increased workloads, they were confronted with stigmatization due to their work in the health sector.
Methods: Guided by the Health Stigma and Discrimination Framework (HSDF), this study aimed to explore the experiences of stigmatization of HCWs in Germany using semi-structured interviews (N = 34) and investigate effective coping strategies and existing needs in this context.
Harnessing community-based one health interventions implementation beyond Mpox outbreak management in Africa: insights and benefits.
Infect Dis Poverty
September 2025
Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon.
Background: Little is documented on key community-based One Health (OH) approach implementation, pro-activeness and effectiveness of interactions and strategies against Mpox outbreak public health emergency in international concern (PHEIC) in various African countries in order to stamp out the persisting Mpox outbreak threat and burden. Prioritizing critical community-based interventions and lessons learned from previous COVID-19, Mpox, Ebola, COVID-19, Rift Valley Fever and Marburg virus outbreaks revealed critical shortcomings in funding, surveillance, and community engagement that plague public health initiatives across the continent. The article provides critical insights and benefits of community-based One Health approaches implementation against Mpox outbreak management in Africa.
View Article and Find Full Text PDFPatient-centred interprofessional teleconsultation for post-viral symptom complexes in German primary care-protocol for the cluster-randomised controlled COVI-Care M-V trial.
BMC Health Serv Res
September 2025
Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, Rostock, 18057, Germany.
Background: Post-viral syndromes, including long- and post-COVID, often lead to persistent symptoms such as fatigue and dyspnoea, affecting patients' daily lives and ability to work. The COVI-Care M-V trial examines whether interprofessional, patient-centred teleconsultations, initiated by general practitioners in cooperation with specialists, can help reduce symptom burden and improve care for patients.
Methods: To evaluate the effectiveness of the intervention under routine care conditions, a cluster-randomised controlled trial is being conducted.
The interplay of influenza and COVID-19 in Germany, January 2020 - December 2022: a study of competitive disease dynamics with quarantine measures and partial cross-immunity.
BMC Public Health
September 2025
Department of Mathematics, Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau, Gottlieb-Daimler-Str.48, Kaiserslautern, 67663, Germany.
We study the dynamics of coexisting influenza and SARS-CoV-2 by adapting a well-established age-specific COVID-19 model to a multi-pathogen framework. Sensitivity analysis and adjustment of the model to real-world data are used to investigate the influence of age-related factors on disease dynamics. Our findings underscore the critical role that transmission rates play in shaping the spread of influenza and COVID-19.
View Article and Find Full Text PDF